Last reviewed · How we verify
NCT05461599
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
NA trial testing SparkRx Mobile App in Depressive Symptoms in 2 participants. Terminated before completion.
16 May 2023
Quick facts
| Lead sponsor | Limbix Health, Inc. |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 25 August 2022 |
| Primary completion | 16 May 2023 |
| Estimated completion | 16 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SparkRx Mobile App
Conditions studied
- Depressive Symptoms — all drugs for Depressive Symptoms →
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Depression — all drugs for Depression →
- Cardiology — all drugs for Cardiology →
Sponsor
Limbix Health, Inc.
Who can join
Adults 13 to 22, any sex, with Depressive Symptoms or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of depression among adolescents being treated in specialty medical care settings at Children's Hospital of Los Angeles (CHLA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05461599
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depressive Symptoms
Currently open trials in the same condition.
- NCT07299903 — IMB-Based Sleep Hygiene Education for Menopausal Women: Effects on Sleep Quality and Depression · NA · recruiting
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07241325 — Psychological Well-Being, Depression, and Health-Related Quality of Life in Adults With Type 2 Diabetes: A Cross-Section · recruiting
- NCT07216326 — Our Voices Matter: Intervention for Depression in Youth · NA · recruiting
Other Limbix Health, Inc. trials
Trials by the same sponsor.
- NCT05351866 — Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management · NA · terminated
- NCT05462652 — Self-guided Treatment for Adolescents Navigating Depression · NA · completed
- NCT04524598 — A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19 · NA · completed
- NCT04165681 — A Mobile and Virtual Reality Intervention for Adolescent Depression · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05461599 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Limbix Health, Inc.
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05461599.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing